Arcellx, Inc.
ACLX
株式のランク
#2784
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
株価
$115.07
最終同期: 2026-05-15
時価総額
$6.73B
変化（1日）
0.00%
変化（1年）
32.28%
国
US
取引 Arcellx, Inc. (ACLX)
カテゴリー
Healthcare
Arcellx, Inc.（ACLX）のEPS
December 2025 時点のEPS TTM: $-4.07
Arcellx, Inc.の最新の財務報告と株価によると、同社の現在のEPS（TTM）は$-4.07です。2023年末には、EPSは$-1.47で、2022年のEPS$-4.28と減少でした。
Arcellx, Inc.のEPS履歴（2018から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2026 (TTM) | $-4.07 | 103.50% |
| 2024 | $-2.00 | 36.05% |
| 2023 | $-1.47 | -65.65% |
| 2022 | $-4.28 | 120.62% |
| 2021 | $-1.94 | 31.97% |
| 2020 | $-1.47 | 182.69% |
| 2019 | $-0.52 | -98.96% |
| 2018 | $-50.17 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $17.32 | -525.55% |
US
|
|
| $-7.98 | 96.07% |
US
|
|
| $-5.29 | 29.98% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -781.57% |
NL
|
